Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

NDAQ:GRCE - Post Discussion

Grace Therapeutics, Inc > For the record
View:
Post by Justhalffull on Sep 05, 2021 4:27pm

For the record

If you had invested $10,000 on Feb 7 2012, you would now have 245.87.  If you need any more evidence about this outfit, you should not be investing in stocks.
Comment by Canadian_101 on Nov 06, 2021 10:12am
What a SH_IT Show this has been, thank god I dumped all my shares and moved on before they announced the final results, my spider sense told me  something was majorly wrong when they delayed the reults,  personally I cannot believe this company is still in business with  the same management team in place after the horribly run trials, BUYER BEWARE is all I can say. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities